NCT01935167

To Determine the Efficacy and Safety of DW1029M on Microalbuminuria in Patients With Diabetic Nephropathy

A Phase Ⅱ, Prospective, 24 Weeks, Double-blind, Placebo-controlled, Randomized, Multi-center Clinical Trial for the Evaluation of the Efficacy and Safety of DW1029M on Microalbuminuria in Patients With Diabetic Nephropathy

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 158 (actual)
• Sponsor: Dong Wha Pharmaceutical Co. Ltd. · Industry
• Sex: All
• Age: 30 Years
• Healthy volunteers: Not accepted

Summary

Phase 2 clinical study to evaluate of the efficacy and safety of DW1029M on microalbuminuria in Patients With Diabetic Nephropathy

Detailed description

A Phase Ⅱ, prospective, 24 weeks, double-blind, placebo-controlled, randomized, multi-center clinical trial for the evaluation of the efficacy and safety of DW1029M on microalbuminuria in Patients With Diabetic Nephropathy

Conditions

• Diabetic Nephropathy

Interventions

Type	Name	Description
DRUG	DW1029M 600mg	DW1029M 150mg 2 tablets b.i.d
DRUG	DW1029M 1200mg	DW1029M 300mg 2 tablets b.i.d
DRUG	Placebo	Placebo 2 tablets b.i.d.

Timeline

• Start date: 2013-10-01
• Primary completion: 2014-08-01
• Completion: 2015-02-01
• First posted: 2013-09-04
• Last updated: 2017-02-17

Locations

1 site across 1 country: South Korea